global
Variables
Utilities
CUSTOM STYLES

FDA Approves Rybrevant (amivantamab-vmjw) for Non-small Cell Lung Cancer with EGFR-Exon 20 Mutation

March 4, 2024

On March 1, 2024, the U.S. Food and Drug Administration (FDA) approved the drug Rybrevant (amivantamab-vmjw) to be given in combination with carboplatin and pemetrexed in the first lining setting for people with metastatic non-small cell lung cancer (NSCLC) with an EGFR exon 20 mutation. They also announced traditional approval for Rybrevant (amivantamab-vmjw) to be given to people with metastatic non-small cell lung cancer (NSCLC) who are positive for an EGFR exon 20 mutation after they have experienced progression or recurrence while on or after platinum-based chemotherapy.This decision is based on the results of the PAPILLON trial. The trial assessed the use of Rybrevant (amivantamab-vmjw) in combination with platinum-based chemotherapy in people living with metastatic non-small cell lung cancer who were also positive for an EGFR exon 20 mutation. This study found that platinum-based chemotherapy combined with Rybrevant (amivantamab-vmjw) resulted in improvement in overall survival when compared to platinum-based chemotherapy alone.The results of this trial and the subsequent approval have provided an exciting new first-line treatment option for people living with advanced/metastatic EGFR exon 20-positive lung cancer. While EGFR mutations are involved in roughly 32% of non-small lung cancer (NSCLC) diagnoses, EGFR exon 20 mutations comprise only 1-12% of these. This alteration tends to be more common in people who are female and those who have not smoked before.Read the full announcement from the FDA here.

This is some text inside of a div block.

Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.